Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Geoffrey Paul Margison is active.

Publication


Featured researches published by Geoffrey Paul Margison.


Biochimica et Biophysica Acta | 1997

The potential role of glycine-160 of human O6-alkylguanine-DNA alkyltransferase in reaction with O6-benzylguanine as determined by site-directed mutagenesis and molecular modelling comparisons

Joseph A Rafferty; Jane E. A. Wibley; Peter Speers; Ian D. Hickson; Geoffrey Paul Margison; Peter C. E. Moody; Kenneth T. Douglas

O6-Alkylguanine DNA-alkyltransferase (ATase) repairs toxic, mutagenic and carcinogenic O6-alkylguanine (O6-alkG) lesions in DNA by a highly conserved reaction involving the stoichiometric transfer of the alkyl group to the active centre cysteine residue of the ATase protein. In the Escherichia coli Ada ATase, which is effectively refactory to inhibition by O6-benzylguanine (O6-BzG), the residue corresponding to glycine-160 (G160) for the mammalian proteins of this class is replaced by a tryptophan (W). Therefore, to investigate the potential role of the G160 of the human ATase (hAT) protein in determining sensitivity to O6-BzG, site-directed mutagenesis was used to produce a mutant protein (hATG160W) substituted at position 160 with a W residue. The hATG160W mutant was found to be stably expressed and was 3- and 5-fold more sensitive than hAT to inactivation by O6-BzG, in the absence and presence of additional calf-thymus DNA respectively. A similar, DNA dependent increased sensitivity of the hATG160W mutant relative to wild-type was also found for O6-methylguanine mediated inactivation. The potential role of the W160 residue in stabilising the binding of the O6-alkG to the protein is discussed in terms of a homology model of the structure of hAT. The region occupied by G/W-160 forms the site of a putative hinge that could be important in the conformational change that is likely to occur on DNA binding. Three sequence motifs have been identified in this region which may influence O6-BzG access to the active site; YSGG or YSGGG in mammals (YAGG in E. coli Ogt, YAGS in Dat from Bacillus subtilis), YRWG in E. coli Ada and Salmonella typhimurium (but YKWS in Saccharomyces cerevisiae) or YRGGF in AdaB from B. Subtilis. Finally,conformational and stereoelectronic analysis of the putative transition states for the alkyl transfer from a series of inactivators of hAT, including O6-BzG was undertaken to rationalise the unexpected weak inhibition shown by the alpha-pi-unsaturated electrophiles.


Archive | 1994

Potentiation of temozolomide in human tumour cells

John Colin Baer; Azadeh Alison Freeman; Edward Stuart Newlands; Amanda Jean Watson; Joseph A Rafferty; Geoffrey Paul Margison


Archive | 1996

Pyrimidine derivatives and guanine derivatives, and their use in treating tumor cells

Thomas Brian Hamilton Mcmurry; Robert Stanley Mcelhinney; Joan E. McCormick; Dorothy Josephine Donnelly; Paul Murray; Christophe Carola; Rhoderick Hugh Elder; Jane Kelly; Geoffrey Paul Margison; Amanda Jean Watson; Joseph A Rafferty; Mark Andrew Willington; Mark R. Middleton


Oncology Research | 1993

Identification of nitrosourea-resistant human rhabdomyosarcomas by in situ immunostaining of O6-methylguanine-DNA methyltransferase

Thomas P. Brent; M A von Wronski; C C Edwards; Michael Bromley; Geoffrey Paul Margison; Joseph A Rafferty; Charles N. Pegram; Darell D. Bigner


Archive | 1994

O6 -substituted guanine derivatives, a process for their preparation and their use in treating tumor cells

Thomas Brian Hamilton Mcmurry; Robert Stanley McBlhinney; Joan E. McCormick; Rhoderick Hugh Elder; Jane Kelly; Geoffrey Paul Margison; Joseph A Rafferty; Amanda Jean Watson; Mark Andrew Willington; Dorothy Josephine Donnelly


Archive | 1995

Pyrimidine and purine derivatives and their use in treating tumour cells

Thomas Brian Hamilton Mcmurry; Robert Stanley Mcelhinney; Dorothy Josephine Donnelly; Paul Murray; Christophe Carola; Rhoderick Hugh Elder; Jane Kelly; Geoffrey Paul Margison; Joseph A Rafferty; Amanda Jean Watson; Mark Andrew Willington


Molecular Carcinogenesis | 1994

bcl-2 delay of alkylating agent-induced apoptotic death in a murine hemopoietic stem cell line.

Leslie J. Fairbairn; Graham J. Cowling; T. Michael Dexter; Joseph A Rafferty; Geoffrey Paul Margison; Brigit M Reipert


Archive | 2010

human O6-alkylguanine-DNA-alkyltransferase of multiple doses of nitrosourea by retrovirus-mediated expression of Long-term protection of hematopoiesis against the cytotoxic effects

Jaroslav Jelinek; Leslie J. Fairbairn; Joseph A Rafferty; Carol B. Stocking; Wolfram Ostertag; Geoffrey Paul Margison


Archive | 1999

Potentiation of temozolomide by an ATase inhibitor

John Colin Baer; Azadeh Alison Freeman; Edward Stuart Newlands; Amanda Jean Watson; Joseph A Rafferty; Geoffrey Paul Margison


Archive | 1996

Derives de la pyrimidine et derives de la guanine, et leur utilisation pour traiter des cellules tumorales

Thomas Brian Hamilton Mcmurry; Robert Stanley Mcelhinney; Joan E. McCormick; Dorothy Josephine Donnelly; Paul Murray; Christophe Carola; Rhoderick Hugh Elder; Jane Kelly; Geoffrey Paul Margison; Amanda Jean Watson; Joseph A Rafferty; Mark Andrew Willington; Mark R. Middleton

Collaboration


Dive into the Geoffrey Paul Margison's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Leslie J. Fairbairn

National and Kapodistrian University of Athens

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge